Brand Intelligence Graphcompany
Company Overview
About Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Business Model & Competitive Advantage
Pfizer's core commercial portfolio extends across oncology, rare disease, internal medicine, and vaccines. Eliquis (apixaban, co-promoted with Bristol-Myers Squibb) remains the world's best-selling anticoagulant; Ibrance leads in CDK4/6 inhibitor breast cancer therapy; Vyndaqel/Vyndamax dominates the ATTR-CM (transthyretin cardiomyopathy) market where it has achieved blockbuster status. The Prevnar pneumococcal vaccine franchise and Nimenrix meningococcal vaccines anchor a diversified global vaccine portfolio. Pfizer's "Fit-to-Win" restructuring program targets $4 billion in annual cost savings by 2025, realigning R&D investments toward the highest-value pipeline opportunities post-Seagen integration.
Competitive Landscape 2025–2026
In 2025-2026, Pfizer confronts significant patent cliff risks: Eliquis faces generic competition beginning in 2026-2028, representing roughly $7 billion in annual U.S. revenues at risk. The Seagen ADC platform is the primary offense against this cliff, with Padcev already generating $1 billion-plus in annual revenues for metastatic urothelial cancer. Competitive pressures come from AstraZeneca (Enhertu in ADCs), Eli Lilly (oncology expansion), and Merck (Keytruda franchise). Activist investor Starboard Value took a stake in late 2024 and has pressed for more aggressive cost cuts and strategic review. Pfizer's GLP-1 obesity drug danuglipron failed Phase 2 trials in 2023, leaving the company without a direct entry in the fast-growing obesity therapeutics market dominated by Eli Lilly and Novo Nordisk.
The Pfizer Story
Founders
Recent Activity
View all →C4891035 zhoum55 Tue, 11/17/2026 - 01:53 Vepdegestrant (ARV-471) Vepdegestrant (ARV-471) PHASE I Fri, 02/23/2024 - 12:00 Fri, 05/24/2024 - 12:00 NCT06275841 C4891035 Public Disclosure Synopsis .pdf (82.57 KB) N https://clinicaltrials.gov/study/NCT06275841?term=C4891035&viewType=Card&rank=1 C4891035
B3461114 zhoum55 Wed, 11/04/2026 - 22:40 Vyndamax® / Vyndaqel® Tafamidis (PF-06291826) PHASE I Tue, 02/27/2024 - 12:00 Mon, 05/27/2024 - 12:00 NCT06273839 B3461114 Public Disclosure Synopsis.pdf (90.18 KB) N https://clinicaltrials.gov/study/NCT06273839?term=B3461114&viewType=Card&rank=1 B3461114
C4531001 zhoum55 Wed, 11/04/2026 - 22:14 PF-07275315 PF-07275315 PHASE I Thu, 06/09/2022 - 12:00 Mon, 05/13/2024 - 12:00 NCT05411588 C4531001 Public Disclosure Synopsis.pdf (317.96 KB) N https://clinicaltrials.gov/study/NCT05411588?term=C4531001&viewType=Card&rank=1 C4531001
C4891039 zhoum55 Wed, 11/04/2026 - 01:51 Vepdegestrant Vepdegestrant PHASE I Thu, 02/08/2024 - 12:00 Mon, 05/13/2024 - 12:00 NCT06256510 C4891039 Public Disclosure Synopsis.pdf (282.11 KB) N https://clinicaltrials.gov/study/NCT06256510?term=C4891039&viewType=Card&rank=1 C4891039
C4521001 zhoum55 Wed, 11/04/2026 - 01:24 PF-07264660 PF-07264660 PHASE I Tue, 08/16/2022 - 12:00 Mon, 05/06/2024 - 12:00 NCT05496738 C4521001 Public Disclosure Synopsis_0.pdf (105.4 KB) N https://clinicaltrials.gov/study/NCT05496738?term=C4521001&viewType=Card&rank=1 C4521001
A Phase 1, Open-Label, Randomized, Single-Dose, Parallel Design, Study to Evaluate Pharmacokinetic Comparability of Two PF-07940367 Film-Coated Tablet Formulations Administered as 150 mg Under Fasted Conditions in Healthy Participants zhoum55 Tue, 11/03/2026 - 03:21 Osivelotor (PF-07940367) Osivelotor (PF-07940367) PHASE I Mon, 01/15/2024 - 12:00 Tue, 05/07/2024 - 12:00 NCT06190561 C5351008 Public Disclosure Synopsis.pdf (101.85 KB) N https://clinicaltrials.gov/study/NCT06190561?term=C5351008&viewType=Card&rank=1 C5351008
Quarterly Report filed 2026-11-03
Material Event filed 2026-11-03
Material Event filed 2026-11-03
A Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Dystrophin Expression After Fordadistrogene Movaparvovec (PF-06939926) Administration in Male Participants With Early Stage Duchenne Muscular Dystrophy reddym75 Fri, 10/30/2026 - 06:30 PF-06939926 Fordadistrogene Movaparvovec PHASE II Mon, 08/08/2022 - 12:00 Fri, 10/03/2025 - 12:00 NCT05429372 C3391008 Public Disclosure Synopsis .pdf (123.37 KB) N https://clinicaltrials.gov/study/NCT05429372 C3391008
A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) zhoum55 Fri, 10/09/2026 - 05:23 Brentuximab vedotin Brentuximab vedotin PHASE III Thu, 08/20/2020 - 12:00 Fri, 01/23/2026 - 12:00 NCT04404283 C5691003 Public Disclosure Synopsis.pdf (143.34 KB) N https://clinicaltrials.gov/study/NCT04404283?term=C5691003&viewType=Card&rank=1 C5691003 (SGN35-031)
A Phase 1/2 Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Varicella Zoster Virus in Healthy Individuals Substudy A Supplemental CSR – Final Phase 1 Analysis zhoum55 Tue, 09/29/2026 - 03:47 PF-07911145 (VZV modRNA Vaccine) PF-07911145 (VZV modRNA Vaccine) PHASE I Wed, 01/25/2023 - 12:00 Fri, 09/19/2025 - 12:00 NCT05703607 C5031001 SSA Public Disclosure Synopsis.pdf (193.7 KB) N https://clinicaltrials.gov/study/NCT05703607?term=NCT05703607&viewType=Card&rank=1 C5031001 Substudy A
Company Timeline
Major milestones in Pfizer's journey
Leadership Team
Meet the leaders behind Pfizer
Dr. Albert Bourla
Albert Bourla is a Greek-American veterinarian and businessman who became CEO of Pfizer in January 2019 and Chairman in February 2019. During his 30+ years at Pfizer, he held senior management positions across five countries and established Pfizer's Purpose Blueprint with core values of Courage, Excellence, Equity, and Joy to create a culture where science and people thrive.
David M. Denton
Dave Denton joined Pfizer as CFO and Executive Vice President effective May 2, 2022, providing strategic global financial leadership as a member of Pfizer's Executive Leadership Team. He oversees all financial operations and strategy for the company.
Dr. Chris Boshoff
Chris Boshoff, M.D., PhD, was appointed Chief Scientific Officer and President of Research & Development effective January 1, 2025, following a comprehensive selection process. Previously Chief Oncology Research and Development Officer, he leads Pfizer's global R&D efforts and scientific strategy.
Aamir Malik
Aamir Malik is Executive Vice President and Chief U.S. Commercial Officer, leading the U.S. Commercial business including Primary and Specialty Care Commercial and Medical Affairs, Oncology Commercial, Global Access and Value, and Global Chief Marketing Office organizations as a member of the Executive Leadership Team.
Dr. Andrew Baum
Andrew Baum, M.D., joined Pfizer as Chief Strategy and Innovation Officer and Executive Vice President, reporting to CEO Dr. Albert Bourla. He is a member of Pfizer's Executive Leadership Team responsible for corporate strategy and innovation initiatives.
Key Differentiators
Market Leader
Pfizer is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $63.6B in revenue, Pfizer operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
BNY Mellon
BNY Mellon—rebranded as BNY in 2024—is the world's largest custodian bank and a global leader in investment services, tracing its origins to the Bank of New York founded in 1784 by Alexander Hamilton.
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Zocdoc
Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati
Doximity
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic
Compare Pfizer with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Pfizer? Verify your company email to claim this profile and keep its description, products, and FAQs up to date.
Claim Pfizer Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Pfizer vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →